Cholesterol absorption blocker ezetimibe prevents muscle wasting in severe dysferlin‐deficient and mdx mice
Abstract Background Muscular dystrophy (MD) causes muscle wasting and is often lethal in patients due to a lack of proven therapies. In contrast, mouse models of MD are notoriously mild. We have previously shown severe human‐like muscle pathology in mdx [Duchenne MD (DMD)] and dysferlin‐deficient li...
Saved in:
Main Authors: | Zoe White (Author), Marine Theret (Author), Nadia Milad (Author), Lin Wei Tung (Author), William Wei‐Han Chen (Author), Martin G. Sirois (Author), Fabio Rossi (Author), Pascal Bernatchez (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Full-length Dysferlin Transfer by the Hyperactive Sleeping Beauty Transposase Restores Dysferlin-deficient Muscle
by: Helena Escobar, et al.
Published: (2016) -
Increased coproporphyrin serum levels in healthy volunteers treated with the cholesterol uptake inhibitor ezetimibe
by: Jonny Kinzi, et al.
Published: (2024) -
Exome sequencing identifies novel dysferlin mutation in a family with pauci-symptomatic heterozygous carriers
by: Mahjoubeh Jalali-, et al.
Published: (2018) -
Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins
by: Harold E. Bays, et al.
Published: (2021) -
Co-Amorphous Formation of Simvastatin-Ezetimibe: Enhanced Physical Stability, Bioavailability and Cholesterol-Lowering Effects in LDLr−/−Mice
by: Shamuha Bahetibieke, et al.
Published: (2022)